Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
Release Date:
2026-03-09 16:48
Conference Background
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
Basic Conference Information
Conference Name: The 3rd Boao Lingshui Stem Cell Conference
Meeting Theme: Cell Therapy Leads the Third Medical Revolution
Meeting Time: March 20–22, 2026
Meeting Location: Boao Lucheng Yihhe Health and Wellness Resort
Conference Organizational Structure
Organizer: China Anti-Aging Promotion Association, Hainan University
Introduction to Hycells
At the Third Boao Lecheng Stem Cell Conference, government authorities provided an in-depth analysis of the approval policies for cell therapy pricing items, the regulatory framework, and future directions for policy adjustments. Leading Nobel laureates presented the latest advances in global basic stem cell research and translational medicine, highlighting the core breakthroughs driving the third medical revolution through cell therapy and outlining future strategic priorities, thereby offering a comprehensive overview of cutting-edge developments and the sector’s long-term vision. As a pioneering company in primary cell technology, Hycells Biotechnology was also invited to attend the conference.
Wuxi Hycells Biotechnology Co., Ltd. (hereinafter referred to as “Hycells Bio”) is a high-tech enterprise specializing in primary immune cell and stem cell technologies, with its headquarters located in the Wuxi Precision Medicine Industrial Park. The company has established a comprehensive, end-to-end technology platform covering both immune cells and mesenchymal stem cells (MSCs). Leveraging a dual-center operational model centered on Wuxi and Shanghai, Hycells Bio strengthens its R&D and translational capabilities: the Wuxi center focuses on product development, manufacturing, and commercialization, while the Shanghai center specializes in the preparation of primary cells and related technical services.
Adhering to the R&D philosophy of “end-to-end process optimization” and “integrated technology,” Hycells Biotechnology has launched a benchmark one-stop culture solution for immune cells and stem cells, creating a comprehensive offering that includes compliant seed cells and HiXpan. Registered trademark Serum-free culture kit, HiXpan Registered trademark An integrated cell culture system that combines cell culture supplements and the four core components of Cell Feeder底透 cell culture flasks, providing customers with efficient, stable, and compliant end-to-end culture support.
Meanwhile, the company continues to expand its product portfolio and service capabilities centered on primary cell technology, having established a business footprint focused on primary immune cells, stem cells, and hepatocytes, which has given rise to HiXpan. Registered trademark The product portfolio includes cell culture kits, the HiMag magnetic bead-based sorting kit series, as well as assay products such as CAR-positive rate detection kits and ELISpot assay kits. In terms of technical services, Hycells Biotechnology offers specialized solutions covering in vitro efficacy evaluation, drug immunogenicity assessment, and hematotoxicity testing, providing precise support for critical stages in biopharmaceutical R&D and manufacturing. Several of its products and services have broken long-standing foreign monopolies, achieving domestic innovation and surpassing international standards, thereby delivering comprehensive, independently controllable solutions to the industry.
Hycells’s star product
HiXpan Registered trademark MSC Serum-Free Culture Kit
FIRE FIGHTING
High-cell yield
High exosome yield
A high-quality, complete culture protocol specifically designed for the primary isolation and serial passaging of human mesenchymal stem cells under serum-free, xeno-free conditions.
Product Advantages:
Safety: Serum-free and free of xenogenic components
Broad-spectrum: Applicable to mesenchymal stem cells derived from multiple tissue sources, such as umbilical cord MSCs, bone marrow MSCs, and adipose-derived MSCs.
High efficiency: faster proliferation, stable passage for more than 10 passages, and better maintenance of cellular differentiation potential.
Convenience: Direct use—no need to add any additional components or coat the microtiter plates.
HiXpan Registered trademark NK Cell Serum-Free Culture Kit (Cytokine-Based)
FIRE FIGHTING
High purity, high amplification efficiency
Efficient induction and expansion of NK cells from human peripheral blood or umbilical cord blood-derived samples.
Product Advantages:
Strong expansion capacity: cells can be expanded up to 500-fold, with a post-expansion viability of ≥90%.
NK cells exhibit high purity and potent cytotoxic activity.
Suitable for fresh or cryopreserved PBMCs and CBMCs.
GMP-grade culture media: safe, stable, and highly efficient.
No antibody coating required; simple and convenient operation.
HiXpan Registered trademark Cell culture
Additives
FIRE FIGHTING
Single donor traceability
Additives with well-defined biological compositions and no animal-derived sources, used in cell culture as substitutes for traditional animal sera such as fetal bovine serum, are designed to reduce batch-to-batch variability, minimize contamination risks, and enhance experimental reproducibility. Their formulations typically include growth factors, carrier proteins, trace elements, and other components, making them suitable for applications in vaccine production, biopharmaceuticals, regenerative medicine, and other fields.
Product Advantages:
Compliance and Traceability: Material sources are compliant and traceable, and suppliers have established independent information traceability documentation and systems.
High performance: Utilizes a proprietary, in-house process to release high-concentration growth factors, significantly accelerating cell proliferation.
Compliant with GMP and regulatory requirements: supports IND submissions and IIT clinical studies.
Meeting Agenda and Procedure
Specialized Forum
1. Special Forum on Cell Therapy for Neurological Disorders
Forum Chair: Li Wenbin
2. Special Forum on Immunocellular Therapy for Diseases
Forum Chair: Wei Yuquan
3. Special Forum on Cell Therapy for Immune Diseases
Forum Chair: Wu Yuzhang
4. Special Forum on Cell Therapy for Women’s Diseases
Forum Chair: Qiao Jie
5. Special Forum on Cell Therapy for Liver Diseases and Major Infectious Diseases
Forum Chair: Wang Fusheng
6. Special Forum on Cell Therapy for Endocrine Diseases
Forum Chair: Deng Hongkui’s Team
7. Oncolytic Virus Symposium
Forum Chair: Shang Yongfeng
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board